[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.", "fullTimeEmployees": 24, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 54, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 894300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas  Maestas", "age": 44, "title": "CFO, Head of Corporate Strategy & Secretary", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 465615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Samuel  Whiting M.D., Ph.D.", "age": 58, "title": "Executive VP, Chief Medical Officer and Head of R&D", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 671387, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Justin  Trojanowski CPA", "age": 36, "title": "Corporate Controller, Treasurer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsay  Young", "title": "Head of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.42, "open": 6.49, "dayLow": 6.2506, "dayHigh": 6.631, "regularMarketPreviousClose": 6.42, "regularMarketOpen": 6.49, "regularMarketDayLow": 6.2506, "regularMarketDayHigh": 6.631, "payoutRatio": 0.0, "beta": -2.215, "forwardPE": -4.804348, "volume": 29863, "regularMarketVolume": 29863, "averageVolume": 61530, "averageVolume10days": 43030, "averageDailyVolume10Day": 43030, "bid": 4.68, "ask": 8.19, "bidSize": 2, "askSize": 2, "marketCap": 24232784, "fiftyTwoWeekLow": 5.356, "fiftyTwoWeekHigh": 47.45, "fiftyDayAverage": 8.91814, "twoHundredDayAverage": 13.122495, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 7558801, "profitMargins": 0.0, "floatShares": 3222289, "sharesOutstanding": 3655020, "sharesShort": 110022, "sharesShortPriorMonth": 134803, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0313, "heldPercentInsiders": 0.00133, "heldPercentInstitutions": 0.14293, "shortRatio": 1.49, "shortPercentOfFloat": 0.0339, "impliedSharesOutstanding": 3753650, "bookValue": 5.655, "priceToBook": 1.1724138, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -41843000, "trailingEps": -19.5, "forwardEps": -1.38, "lastSplitFactor": "1:13", "lastSplitDate": 1744156800, "enterpriseToEbitda": -0.182, "52WeekChange": -0.8576812, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 6.63, "targetHighPrice": 207.99994, "targetLowPrice": 9.0, "targetMeanPrice": 102.99997, "targetMedianPrice": 97.49997, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 30268000, "totalCashPerShare": 8.651, "ebitda": -41637000, "totalDebt": 15365000, "quickRatio": 2.129, "currentRatio": 2.213, "debtToEquity": 80.336, "returnOnAssets": -0.56431, "returnOnEquity": -1.82346, "freeCashflow": -19081750, "operatingCashflow": -33027000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "TPST", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "longName": "Tempest Therapeutics, Inc.", "shortName": "Tempest Therapeutics, Inc.", "regularMarketChangePercent": 3.2710285, "regularMarketPrice": 6.63, "corporateActions": [], "regularMarketTime": 1746723353, "exchange": "NCM", "messageBoardId": "finmb_552715229", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1352730600000, "regularMarketChange": 0.21000004, "regularMarketDayRange": "6.2506 - 6.631", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 61530, "fiftyTwoWeekLowChange": 1.2740002, "fiftyTwoWeekLowChangePercent": 0.2378641, "fiftyTwoWeekRange": "5.356 - 47.45", "fiftyTwoWeekHighChange": -40.82, "fiftyTwoWeekHighChangePercent": -0.86027396, "fiftyTwoWeekChangePercent": -85.76812, "dividendDate": 1544400000, "earningsTimestamp": 1743106257, "earningsTimestampStart": 1746701940, "earningsTimestampEnd": 1747051200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -19.5, "epsForward": -1.38, "epsCurrentYear": -13.66333, "priceEpsCurrentYear": -0.48524043, "fiftyDayAverageChange": -2.2881403, "fiftyDayAverageChangePercent": -0.25657147, "twoHundredDayAverageChange": -6.4924946, "twoHundredDayAverageChangePercent": -0.4947607, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Tempest Therapeutics Inc.", "nameChangeDate": "2025-05-07", "averageAnalystRating": "2.3 - Buy", "hasPrePostMarketData": true, "displayName": "Tempest Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]